Mounjaro and Oral Contraceptives: the Absorption Issue Explained

The misconception: Mounjaro only interacts with food, not medicines

A common assumption is that Mounjaro's effect on the gut only slows down meals. In reality, tirzepatide reduces gastric motility broadly, which means anything taken by mouth, including a contraceptive tablet, spends longer in the stomach and may be absorbed at a lower rate than it would be otherwise.

This is not a rare or theoretical risk. The Mounjaro SmPC and NHS guidance specifically flag it for oral contraceptives, because even a modest reduction in hormone absorption could reduce contraceptive effectiveness during a critical window. A question our prescribers hear most weeks is whether the pill still works on Mounjaro, and if you want to understand the specifics before speaking to a clinician, our page on Mounjaro and the contraception pill sets out what the guidance actually says about absorption and what it means for your cover. The honest answer is that we don't know exactly how much absorption is affected in any one person, so the guidance takes a precautionary approach.

The precaution recommended across UK clinical guidance, including information from NHS England's weight-management-injections resource, is to use an additional non-oral contraceptive method (barrier methods like condoms are the most practical) for the first four weeks of starting Mounjaro and for four weeks after every dose increase. That window corresponds to the period of greatest change in gastric transit. You can read the full detail of what NHS England sets out for patients starting weight-management injections in their guidance on weight-management injections.

Does this apply to all hormonal contraceptives, or just the pill?

The absorption concern is specific to oral forms of contraception. Non-oral methods (the implant, the injection, the hormonal coil (IUS), the copper coil (IUD), the patch and the vaginal ring) do not rely on gut absorption and are therefore unaffected by tirzepatide's effect on gastric emptying. If you are considering switching to one of these methods, a contraception review with your GP or sexual health service is the right starting point.

For anyone already using a non-oral method, there is no equivalent warning in the UK prescribing guidance. The implant, for example, sits in your arm and delivers hormones directly into the bloodstream, the gut plays no part.

It is also worth knowing that this specific precaution (adding a barrier method during the early weeks) does not appear in UK guidance for injectable semaglutide (Wegovy). The mechanism behind this difference lies in how tirzepatide, as a dual GIP and GLP-1 receptor agonist, affects gastric emptying compared to a single-receptor agonist. The clinical evidence reviewed for the Mounjaro SmPC flagged it; the same body of evidence for Wegovy did not. That said, if you have specific concerns about semaglutide and the pill, raise them with your prescriber.

Pregnancy, fertility, and timing

Mounjaro is not licensed for use during pregnancy, and it is not recommended for women who are breastfeeding. Animal studies have shown effects on foetal development; there is not yet enough human data to establish safety in pregnancy. Anyone who thinks they might be pregnant while on tirzepatide should stop treatment and contact their GP or prescriber immediately.

For women planning to conceive, stopping Mounjaro in advance and allowing an appropriate washout period before trying is the standard advice, your prescriber can help you think through the timing, since weight regain after stopping is a real consideration for some people. The question of how tirzepatide affects fertility more broadly is an active area of research, and the current guidance is to discuss it with a clinician before making any changes.

There is also a practical point worth noting for women of childbearing age on Mounjaro: weight loss itself can alter menstrual cycle patterns and, in some cases, affect fertility in ways that were not expected. This is not unique to tirzepatide, significant weight change of any kind can influence hormone levels. It is another reason why contraception during tirzepatide treatment deserves a proper conversation, not just a quick read of a leaflet.

Who to speak to, and when

If you are currently on the oral contraceptive pill and considering Mounjaro, the most useful step is to raise it with your GP and your prescriber before you start. They can look at your full contraceptive history and any other medicines you take, and make a specific recommendation. The NHS tirzepatide medicines page summarises the key interactions to be aware of, including this one.

For anyone already on Mounjaro who did not know about the pill interaction, the guidance is the same: add a non-oral method now for the next four weeks (or four weeks from your last dose increase, whichever is more recent), and speak to your GP. There is no need to stop Mounjaro; just close the gap in contraceptive cover while your body adjusts to the current dose.

At nume, a GPhC-registered prescriber reviews every consultation the same day, and the interaction between tirzepatide and oral contraceptives is part of that clinical assessment, not an afterthought. Our prescribers flag it and discuss what to do; you can explore the wider topic of how Mounjaro interacts with the contraceptive pill or what the evidence says about pill effectiveness on tirzepatide before you come to a decision. If you're ready to talk to a prescriber, check your eligibility with a free consultation.